GCM
ADVM

Gruss Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Gruss Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-26,000
Closed -$1.34M – 32
2016
Q1 		$1.34M Hold
26,000
– – 0.04% 46
2015
Q4 		$2.48M Hold
26,000
– – 0.08% 66
2015
Q3 		$2.14M Buy
+26,000
New +$3.32M 0.07% 69

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Gruss Capital Management's ADVM Position: Q2 2016 in Review

Gruss Capital Management sold out of Adverum Biotechnologies (ADVM) in Q2 2016, closing a stake of 26,000 shares — an estimated $1.34M sold.

Gruss Capital Management first reported a position in ADVM in Q3 2015 and held it in 3 quarters. The position peaked at $2.48M in Q4 2015. 77 funds tracked by Wall St. Rank hold ADVM as of Q2 2016.

  • Gruss Capital Management reported no remaining Adverum Biotechnologies position as of Q2 2016 after selling out during the quarter.
  • Gruss Capital Management sold 26,000 Adverum Biotechnologies shares in Q2 2016, an estimated $1.34M.
  • Gruss Capital Management first reported a position in Adverum Biotechnologies in Q3 2015 and held it in 3 quarters.
  • Gruss Capital Management's Adverum Biotechnologies position peaked at $2.48M in Q4 2015.
  • 77 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2016.

Based on Gruss Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.